When data from the same cohort were presented in more than one article, only the reports that most directly evaluated therapy with CP (or hyperimmune plasma) and COVID-19 (or SARS-COV-2 infection) in pregnancy were included in this review. This evidence concerns the gene CP and COVID-19.